BioMarin Pharmaceuticals BMRN Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's goodwill?
- BioMarin Pharmaceuticals (BMRN) reported goodwill of $196.2M in Q1 2026.
- How has BioMarin Pharmaceuticals's goodwill changed year-over-year?
- BioMarin Pharmaceuticals's goodwill decreased by 0.0% year-over-year, from $196.2M to $196.2M.
- What is the long-term trend for BioMarin Pharmaceuticals's goodwill?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $196.2M to $196.2M.
- What does goodwill mean?
- The excess amount paid for an acquisition over the fair value of its net assets.
- How do you interpret goodwill?
- A stable or growing balance indicates successful past acquisitions, while a sudden decrease signals an impairment charge due to poor performance of acquired assets.
- How does goodwill compare across companies?
- Common in the pharmaceutical industry due to frequent M&A activity aimed at replenishing drug pipelines.